Angelini Pharma Presents Long-Term Data for cenobamate (ONTOZRY®) Demonstrating Sustained Benefit in Adults with Epilepsy Experiencing Uncontrolled Focal Seizures
Findings from a post-hoc analysis of the C017 open-label extension study demonstrated 23.6% of patients receiving adjuvant treatment with Cenobamate achieved sustained seizure freedom for at least one year.